期刊文献+

CFTR抑制ApoE^(-/-)鼠高同型半胱氨酸血症诱导的肝损伤 被引量:3

CFTR suppressing hyperhomocysteinemia-induced hepatocyte damage in ApoE^(-/-) mice
下载PDF
导出
摘要 目的:探讨囊性纤维化跨膜转导调节因子(CFTR)在高同型半胱氨酸血症(HHcy)致ApoE^(-/-)鼠肝损伤中的作用。方法:5周龄雄性ApoE^(-/-)鼠36只随机分为模型对照组、模型组和治疗组,分别给予普通、高蛋氨酸、高蛋氨酸加叶酸饮食,C57BL/6J雄鼠12只,普通饮食,为正常对照组。检测小鼠血清Hcy、ALT和AST变化,Hcy(100μmol/L)及100 Hcy+F(100μmol/L Hcy+叶酸)干预肝细胞后,检测肝组织和细胞内CFTR m RNA和蛋白水平,分析CFTR激动剂(VX-770)与抑制剂[CFTR(inh)-17]干预细胞后对CFTR表达及ALT和AST含量的影响。结果:模型组ApoE^(-/-)鼠血清Hcy、ALT和AST显著升高,CFTR表达下降(P<0.05),而治疗组可拮抗Hcy、ALT、AST、CFTR的改变(P<0.05);Hcy(100μmol/L)引起肝细胞CFTR表达降低而ALT和AST升高(P<0.05),叶酸对这一改变起缓解作用。VX-770和CFTR(inh)-17干预后可改变肝细胞内ALT和AST含量。结论 :CFTR通过调控ALT和AST抑制HHcy致肝细胞损伤过程。 Objective To investigate the function of CFTR in ApoE^-/- mice with HHcy-induced hepatocellular injury. Methods Thirty six 5-week old ApoE^-/- mice were divided into three groups, including the ApoE^-/- group, the HHcy group and the intervention group,(n = 12). Twelve normal C57 BL / 6J mice were fed with regular mouse diet as the normal control(SPF grade). HL-7702 human liver cells were intervened by Hcy(100 μmol / L) and 100 μmol / L Hcy + folic acid(100 μmol / L Hcy + F). The changes of Hcy, ALT and AST in the serum and the expression of CFTR m RNA and protein in liver and liver cells were detected. The concentrations of ALT and AST in the liver cell intervened by VX-770 agonist and CFTR(inh)-172 inhibitor were measured by ELISA. Results Compared with the control group, the levels of Hcy, ALT and AST were higher and the levels of CFTR m RNA and protein were lower in the Meth group(P〈0.05), while the reverse result in the Meth + F group(P〈0.05). Compared with the control group, the levels of CFTR m RNA and protein were decreased and the levels of ALT and AST were increased in the 100 μmol / L Hcy group(P〈0.05). Compared with the 100 μmol / L Hcy group, the levels of CFTR m RNA and protein were increased and the levels of ALT and AST were decreased in the 100 μmol / L Hcy + F group(P〈0.05). Stimulated with VX-770 can reduce the concentrations of ALT and AST and the vice versa in the CFTR(inh)-17 group the concentration was increased in liver cells. Conclusion CFTR plays an important role in the regulation of hepatocellular injury by HHcy.
出处 《实用医学杂志》 CAS 北大核心 2016年第10期1574-1577,共4页 The Journal of Practical Medicine
基金 国家自然科学基金项目(编号:81360073 81460121) 宁夏医科大学校级科研项目(编号:XY201506 XY201505)
关键词 高同型半胱氨酸血症 囊性纤维化跨膜转导调节因子 肝损伤 ApoE^-/-鼠 Hyperhomocysteinemia Cystic fibrosis transmembrane conductance regulator Hepatocel lular injury ApoE^-/- mice
  • 相关文献

参考文献9

  • 1洪诸权,康建翼,潘莹.血清同型半胱氨酸对冠状动脉粥样硬化性心脏病患者脑卒中发病的影响[J].中国现代医学杂志,2016,26(3):68-71. 被引量:21
  • 2VARATHARAJALU R, GARIGE M, LECKEY LC, et al. Pro- tective Role of Dietary Curcumin in the Prevention of the Oxida- tive Stress Induced by Chronic Alcohol with respect to Hepatic Injury and Antiatherogenic Markers [J]. Oxid Med Cell Longev, 2016,5017460.
  • 3BRENNAN SC, WILKINSON WJ, TSENG HE, et al. The ex- tracellular calcium-sensing receptor regulates human fetal lung development via CFTR [J]. Sci Rep, 2016,6:21975.
  • 4DONG ZW, CHEN J, RUAN YC, et al. CFTR-regulated MAPK/ NF-KB signaling in pulmonary inflammation in thermal inhala- tion injury [J]. Sci Rep, 2015,5:15946.
  • 5徐三彬,郑建普,刘宗军.血清同型半胱氨酸水平与冠状动脉病变严重程度的相关性[J].实用医学杂志,2015,31(19):3231-3234. 被引量:12
  • 6DAI Y, ZHU J, MENG D, et al. Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis [J]. J Clin Biochem Nutr, 2016,58( 1 ) : 76-83.
  • 7SETI'E LH, ALMEIDA LOPES EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a com- prehensive review [J]. CIinies (Sao Paulo), 2014,69(4) :271- 278.
  • 8王秋琼,秦光梅.CFTR在囊性纤维化治疗中的研究现状及展望[J].实用医学杂志,2013,29(20):3433-3435. 被引量:3
  • 9PRATIC0 AD, PRATIC0 ER, ROTOLO N, et al. Isolated liver disease in a patient with a cf'rR genotype F508del/12TG-5T and 470blV: A new face of an old disease [J]. Ann Hepatol, 2015,14 (6) : 933-936.

二级参考文献52

  • 1游明瑶,何珊,赵艳,蔡立君.血清内脂素及同型半胱氨酸水平与动脉粥样硬化性脑梗死的关系[J].中国老年学杂志,2014,34(10):2623-2624. 被引量:13
  • 2Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis [J]. Eur Respir Rev, 2013,22 (127) : 58-65.
  • 3Wilschanski M. Novel therapeutic approaches for cystic fibrosis [J]. Discov Med, 2013,15(81) : 127-133.
  • 4Sermet-Gaudelus I. Ivaeafior treatment in patients with cystic fibrosis and the G551D-CFTR mutation [J]. Eur Respir Rev, 2013,22(127) :66-71.
  • 5Wilsehanski M, Miller L L, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis [J]. Eur Respir J, 2011,38 ( 1 ) :59-69.
  • 6Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date [J] Drugs, 2010,70(3) :241-259.
  • 7Davies J C, Alton E W. Gene therapy for cystic fibrosis [J]. Proc Am Thorae Soc, 2010,7(6) :408-414.
  • 8Griesenbaeh U, Alton E W. Progress in gene and cell therapy for cystic fibrosis lung disease [J]. Curt Pharm Des, 2012,18(5) :642-662.
  • 9Conese M, Aseenzioni F, Boyd A C, et al. Gene and cell therapy for cystic fibrosis : from bench to bedside [ J]. J Cyst Fibros, 2011,10 (Suppl 2) : S114- S128.
  • 10Vecsler M, Ben Z B, Nudelman I, et al. Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsensemutations [J]. Pl_oS One, 2011,6(6): e20733.

共引文献33

同被引文献34

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部